Mickael Worms-Ehrminger, PhD

Just launched! #EuroHePP – a new interactive toolkit from European Centre for Disease Prevention and Control (ECDC) and European Union Drugs Agency (EUDA) designed to support efforts to eliminate hepatitis B and C in prisons across Europe. It offers practical guidance for: ✅ Conducting a health needs assessment ✅ Strategy development ✅ Service implementation ✅ Monitoring & evaluation Explore the toolkit and take action toward hepatitis elimination: https://lnkd.in/dRqigfpC #HepatitisAwareness #PublicHealth #PrisonHealthcare

121

🌍 The Specialized Master in Public Health Methodology, offered through the ARES International Training scholarships in Belgium, is now open for applications for the 2026–2027 academic year. This unique program provides advanced methodological training for public health professionals, with a special focus on equipping those working in low- and middle-income countries to address pressing health challenges. The program is designed to prepare graduates to design, lead, implement, and evaluate impactful public health interventions at local, national, and global levels. 📚 The master’s degree is taught in English and runs for one academic year, with 10 scholarships available. It is a joint effort by three leading Belgian universities: Université libre de Bruxelles (ULB), Université catholique de Louvain (UCLouvain), and Université de Mons (UMONS). Through this collaboration, students gain exposure to diverse expertise across public health, medicine, economics, and applied research, ensuring a strong foundation to address complex health systems and global health priorities. 🗓️ Applications open on 4 August 2025 and close on 19 September 2025 (UTC+1). Interested candidates must apply exclusively through the GIRAF platform, as documents shared by email or messaging apps are not accepted. This program is a powerful opportunity for professionals passionate about advancing health equity, strengthening health systems, and contributing to international health development. If this aligns with your aspirations—or if you know someone who would benefit—be sure to explore and share this opportunity. https://lnkd.in/dRBJYAyq #PublicHealth #GlobalHealth #Scholarship

172

7 commentaires

🚨 New Publication Alert! 🚨 Thrilled to share our latest research, just published in PLOS Digital Health: “Opportunistic use of Artificial Intelligence with X-Ray Imaging for Diagnosis of HIV Status in Tuberculosis Patients in Uganda and Tanzania” 📄 Link to paper: https://lnkd.in/e5uixcAQ 🤖🩻 In this study, we explored how AI can unlock hidden insights from routine chest X-rays—not just for TB screening, but also for inferring HIV status. A potential game-changer for low-resource settings. 🌍 Why it matters for Africa: 💡 In regions like Uganda 🇺🇬 and Tanzania 🇹🇿 where TB and HIV burdens are high and resources are limited, this approach offers a cost-effective, scalable solution by leveraging existing imaging workflows. Key takeaways: ✅ AI adds diagnostic value without additional tests ✅ Dual screening = greater efficiency & impact ✅ Supports earlier diagnosis & better health outcomes ✅ Moves us closer to equitable, tech-powered global health 🌐 🙏 Grateful to lead author Dmitrii Cherezov for driving this effort along with co-authors Tanmoy Dam, and our fantastic collaborators from Tanzania and Uganda, Drs Irene Najjingo, Margaret Mbabazi, Harriet Kisembo, Bruce J KIRENGA, grace soka, Ester Ngadaya, and Sayoki Mfinanga for making this possible. Let’s continue pushing the boundaries of what AI can do in global health. #AI #GlobalHealth #DigitalHealth #TB #HIV #Africa #MedicalImaging #Innovation #HealthcareAI #PLOSdigitalhealth

86

1 commentaire

📢 Publication alert! The paper titled ‘Claudin-1 is a mediator and therapeutic target in primary sclerosing cholangitis’ was published in the Journal of Hepatology https://lnkd.in/e-bDAFm6 Primary sclerosing cholangitis (PSC) remains a disease with high unmet medical need, with no therapies currently approved and disease progression often resulting in liver failure and the need for liver transplantation. This publication highlights Claudin-1 as a potential therapeutic target, showing that its expression is markedly upregulated and associated with progressive liver damage in PSC patients. In mouse models of advanced PSC, treatment with a Claudin-1–specific monoclonal antibody improved liver function and survival by reducing both fibrosis and cholestasis. Importantly, the therapy also suppressed pro-inflammatory and pro-fibrotic signaling in liver tissue explants from PSC patients. Congratulations to our founder Pr. Thomas Baumert and Dr. Fabio Del Zompo at the University of Strasbourg as we share our paper supporting the therapeutic rationale for targeting Claudin-1 in PSC. #AlentisTherapeutics #Hepatology #Cholangitis #BiliaryFibrosis #Claudin #CLDN1

134

#WHO has released its latest guidance for measuring the prevalence of #tuberculosis in high-burden countries. Knowing the extent of #TB is crucial, so countries can devote the resources needed to #EndTB TB-CRE Centre for Research Excellence in Tuberculosis Control Ben J Marais Australasian Clinical Tuberculosis Network (ACTnet) Justin Denholm Stephen Graham Sarah Bernays https://lnkd.in/gwRS2t8m

39

1 commentaire